Here’s what you should know.
1. At Valeant’s annual meeting, Mr. Papa that the company is considering alternative names.
2. Valeant appointed Mr. Papa CEO in May 2016 and has attempted to settle the company’s $30 billion in debt.
3. The potential name change sent company stocks up 8.5 percent early May 2 to $10.19 at noon.
4. In addition to the potential name change, Mr. Papa said Valeant entered the second phase of a three-phase transformational plan. This phase focuses on specialty markets and fixing its balance sheet. Mr. Papa expects the company will enter its third phase, one focused on growth, next year.
More articles on improving health:
Analysts weigh in on Allergan Q1 EPS & more — 4 updates on GI companies
Envision reports 9.2% increase in Q1 physician services net revenue; to divest medical transportation services: 11 things to know
HCA Holdings to become HCA Healthcare: 5 things to know about the change
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.